

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chen, James

Serial No.: 09/905,777

Confirmation No.:5738

Filed: July 13, 2001

For: *Noninvasive Vascular Therapy*

Art Unit: 1614

Examiner: Unassigned



CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number

EV 175672820US


Date of Deposit September 25, 2002

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and addressed to:

U.S. Patent and Trademark Office  
Commissioner for Patents  
P.O. Box 2327  
Arlington, VA 22202

09/25/02

Date



**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98**

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed prior to receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. The Forms PTO-1449 (1 page) and cited references are provided herewith.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to

U.S.S.N. 09/905,777

Chen

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and make them of record in the file history of the above-captioned application.

\* \* \*

Respectfully submitted,  
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

  
\_\_\_\_\_  
Stephanie L. Seidman  
Registration No. 33,779

Attorney Docket No. 25886-0057

**Address all correspondence to:**

Stephanie L. Seidman, Esq.

HELLER, EHRMAN, WHITE & McAULIFFE LLP

4350 La Jolla Village Drive, 7th Floor


San Diego, California 92122-1246

Telephone: (858) 450-8400

Facsimile: (858) 587-5360

EMAIL: sseidman@hewm.com

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 25886-0057	SERIAL NO. 09/905,777
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT Chen, James	
	FILING DATE 07/13/01	GROUP 1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
A	0 0 4 9 2 4 7	04/25/02	Chen	514	410	01/12/01
B	0 0 8 7 2 0 5	07/04/02	Chen	607	88	07/13/01

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
C 0 1 4 3 8 2 5	06/21/01	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

D	Barr <i>et al.</i> , "Normal Tissue Damage Following Photodynamic Therapy: Are There Biological Advantages?", Photodynamic Therapy, Basic Principles and Clinical Applications, Henderson, Barbara W. and Dougherty, Thomas J., (Eds.); Marcel Dekker, Inc., New York; pages 201-216
E	Gilson <i>et al.</i> , "Therapeutic ratio of photodynamic therapy in the treatment of superficial tumours of skin and subcutaneous tissues in man", <i>J. Cancer</i> , <u>58</u> :665-667 (1988)
F	Haas <i>et al.</i> , "Phototherapy of Bladder Cancer: Dose/Effect Relationships", <i>Journal of Urology</i> , 136:525-528 (1986)
G	Lin <i>et al.</i> , "Skin Necrosis due to Photodynamic Action of Benzoporphyrin Depends on Circulating Rather than Tissue Drug Levels: Implications for Control of Photodynamic Therapy", <i>Photochem. Photobiol.</i> , <u>68</u> (4):575-583 (1998)
H	Mew <i>et al.</i> , "Ability of Specific Monoclonal Antibodies and Conventional Antisera Conjugated to Hematoporphyrin to Label and Kill Selected Cell Lines Subsequent to Light Activation", <i>Cancer Res.</i> , <u>45</u> :4380-4386 (1985)
	Parrish, J.A. "Photobiologic Consideration in Photoradiation Therapy," <u>Porphyryn Photosensitization</u> , Plenum Press, 91-108 (1983)
	Tomio <i>et al.</i> , "Effect of Hematoporphyrin and Red Light on AH-130 Solid Tumors in Rats", <i>ACTA Radiologica Oncol.</i> , <u>22</u> :49-53 (1983)
K	Yumita <i>et al.</i> , "The Combination Treatment of Ultrasound and Antitumor Drugs on Yoshida Sarcoma", <i>Japan J. Hyperthermic Oncol.</i> , <u>3</u> (2):175-182 (1987)

TECH CENTER / 630 / 2000  
 OCT 01 2002  
 RECEIVED

EXAMINER /Karen A. Canella, Ph.D./	DATE CONSIDERED 06/10/2010
------------------------------------	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **Noninvasive Vascular Therapy**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KAC/